Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer

Yangjiong Xiao 1,2†, Yang Yu 2†, Dan Gao 2, Wangrui Jin 2, Pengcheng Jiang 3, Yuhong Li 4, Chao Wang 4, Yuning Song 5, Peng Zhan 6, Fei Gu 1, Cancan Zhang 1, Bin Wang 1, Yihua Chen 1,2*, Bing Du 1,2* and Rong Zhang 1*

1 Department of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China, 2 Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China, 3 Department of Gynecology, Changzhou Second People’s Hospital Affiliated to Nanjing Medical University, Changzhou, China, 4 Department of Gynecology, The International Peace Maternity & Child Health Hospital, The China Welfare Institute, Shanghai Jiao Tong University, Shanghai, China, 5 Department of Clinical Pharmacy, Qilu Hospital of Shandong University, Jinan, China, 6 Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, China

Novel inhibitors are urgently needed for use as targeted therapies to improve the overall survival (OS) of patients with ovarian cancer. Here, we show that cell division cycle 25B (CDC25B) is over-expressed in ovarian tumors and associated with poor patient prognosis. All previously reported CDC25B inhibitors have been identified by their ability to reversibly inhibit the catalytic dephosphorylation activity of CDC25B in vitro; however, none of these compounds have entered clinical trials for ovarian cancer therapy. In this study, we synthesized a novel small molecule compound, WG-391D, that potently down-regulates CDC25B expression without affecting its catalytic dephosphorylation activity. The inhibition of CDC25B by WG-391D is irreversible, and WG-391D should therefore exhibit potent antitumor activity against ovarian cancer. WG-391D induces cell cycle progression arrest at the G2/M phase. Half maximal inhibitory concentration (IC50) values of WG-391D for inhibition of the proliferation and migration of eight representative ovarian cancer cell lines (SKOV3, ES2, OVAR8, OVTKO, A2780, IGROV1, HO8910PM, and MCAS) and five primary ovarian tumor cell lines (GFY004, GFY005, CZ001, CZ006, and CZ008) were lower than 10 and 1 µM, respectively. WG-391D inhibited tumor growth in nude mice inoculated with SKOV3 cells or a patient-derived xenograft (PDX). The underlying mechanisms were associated with the down-regulation of CDC25B and subsequent inactivation of cell division cycle 2 (CDC2) and the serine/threonine kinase, AKT. In conclusion, this study demonstrates that WG-391D exhibits strong antitumor activity against ovarian cancer and indicates that the down-regulation of CDC25B by inhibitors could provide a rationale for ovarian cancer therapy.

Keywords: WG-391D, ovarian cancer, PDX, primary cell lines, target therapy
INTRODUCTION

Ovarian cancer is one of the most common malignances in females. The American Cancer Society estimated that there were 22,240 cases of ovarian cancer, and 14,070 deaths, in the United States in 2018 (1). During its early stages, ovarian cancer can be asymptomatic; hence, ∼70% of patients have advanced disease when diagnosed and ultimately develop chemotherapeutic drug resistance and tumor recurrence (2). The death rate from ovarian cancer worldwide has remained as high as 60% over the previous two decades, giving this cancer the highest mortality rate of all gynecological malignances (1, 3).

Novel reagents or treatment strategies, particularly for tumors resistant to chemotherapy, are therefore needed to improve the outcomes of surgery and chemotherapy in ovarian cancer patients (2).

As an increasing number of mechanisms underlying ovarian carcinogenesis and progression are being uncovered, opportunities arise for the development of novel therapeutic drugs with which to improve patient survival by targeting specific cancer-associated molecules. In preclinical and clinical studies, a growing number of drugs and strategies have been adopted to prevent disease progression, inhibit recurrence, and reverse drug resistance to chemotherapeutic agents, such as carboplatin and/or paclitaxel. Most anti-cancer therapies under clinical or preclinical development primarily target molecules which play critical roles in malignant transformation, including cancer cell proliferation, invasion, angiogenesis, and stress responses (4). Olaparib, an enzyme poly ADP ribose polymerase (PARP) inhibitor, was approved by the FDA in 2014, and has been one of the most impressive successes in the development of small molecule compounds for ovarian cancer chemotherapy.

PARP is a key factor in the repair of single-strand DNA breaks (5) and the inhibition of PARP causes massive DNA damage, resulting in cell cycle arrest and apoptosis; however, the reported immature overall survival (OS) was not significantly different when compared between Olaparib therapy and placebo groups (58% maturity and 24% maturity in phases 2 and 3, respectively) (6, 7). The folate receptor (FR) plays an important role in transporting folate into cells for use in DNA synthesis, repair and methylation. Anti-FR antibody and a folate-conjugated vinca alkaloid are the two main therapeutic strategies that have been included in clinical trials targeting FR (4). Unfortunately, these two strategies both failed in phase III clinical trials (4, 8). Vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and angiopoietin (Ang 1 and 2) are key factors involved in angiogenesis (9). However, a total of ten anti-angiogenic trials in phase II and III, which enrolled 7,530 patients with gynecological cancers, showed only a slight increase in progression-free survival (PFS) of 3.3 months, relative to control groups (9). PD-L1 is abundantly expressed in cancer and tumor-infiltrating immune cells in the tumor microenvironment and suppresses T cell activation (10). PD-1/PD-L1 antibodies, which are able to block the suppressive signaling cascade, have been tested extensively for the treatment of various cancers, including ovarian cancer. The response rates of ovarian patients to PD-1 or PD-L1 antibodies ranged from 6 to 15%, and the median duration of PFS was only ∼6 months (11, 12). In summary, although strenuous efforts have been made to develop chemo- and immuno-therapy strategies, the OS of patients with ovarian cancer has only been extended by only a small margin. Hence, novel strategies against ovarian cancer are urgently needed to improve OS of patients.

In this study, we found that CDC25B was over-expressed in ovarian tumors compared with normal ovarian tissues. Furthermore, according to analysis using the Kaplan Meier-plotter online tool, CDC25B expression was positively associated with poor prognosis in ovarian cancer patients. These data strongly indicate that CDC25B plays a critical role in the occurrence and metastasis of ovarian cancer. Hence, CDC25B is a potentially valuable target in the development of chemotherapeutics for the treatment of ovarian cancer. CDC25 is a serine and threonine dual specificity phosphatase, which has three isoforms, CDC25A, CDC25B, and CDC25C, in mammalian cells. CDC25B is an initiator of mitosis that plays a key role in controlling G2/M cell cycle phase transition (13–16). CDC25B dephosphorylates and activates CDC2, which is required for entry into mitosis, and is over-expressed in various tumors, including breast cancer (17), colorectal carcinoma (18), endometrioid endometrial carcinoma (19), esophageal squamous cell carcinoma (20), pancreatic ductal adenocarcinoma (21), and non-small cell lung carcinoma (22), among others. CDC25B inhibitors, which are reported to inhibit the progression of cancer in a highly efficient manner, are primarily vitamin K analogs (23), NSC 663284 (24), naphthofurandione 3-benzoyl-naphtho[1,2-b]furan-4,5-dione (5169131) (25), adocaiquinone B (26), IRC-083864, and BN82685 (27, 28); however, these compounds have mainly been studied in breast cancers, colorectal carcinoma, hematological malignancies, and non-small cell lung carcinoma, while far less is known about the efficiency of these inhibitors in ovarian cancers. All of these compounds were screened out using in vitro chemical assays because they reversibly inhibit the catalytic dephosphorylation activity of CDC25B, but none have entered clinical trials for ovarian cancer therapy. Novel CDC25B inhibitors with high efficiency could be very valuable for the clinical treatment of ovarian cancer. Yuning Song and colleagues previously reported a CDC25 inhibitor, CHEQ-2, that not only inhibited the catalytic dephosphorylation activity of CDC25A and CDC25B in vitro, but also down-regulated CDC25A and CDC25B levels in cancer cells (29). It would be particularly useful if such inhibitors could avoid the reversion of dephosphorylation activity inhibition because of increased CDC25 protein expression levels.

We hypothesized that CDC25B down-regulators could be valuable for targeted therapies against ovarian cancer. In this study, a novel small molecule compound, WG-391D, synthesized in our laboratory, was found to efficiently inhibit the expression, but not the catalytic dephosphorylation activity, of CDC25B in ovarian cancer cells. Hence, WG-391D could represent a potent inhibitor of ovarian cancer tumorigenesis. Our data show that WG-391D not only inhibited ovarian cancer cell proliferation and migration in vitro, but also impeded tumor growth in BALB/c athymic nude mice inoculated with ovarian cancer cells or patient-derived
WG-391D was added at 0° C for 15 min, then 3-amino-propanol was added to the mixture, which was then stirred for a further 3 h, diluted with H2O, and extracted using EtOAc. The combined organic phase was then dried over anhydrous Na2SO4, concentrated, and subjected to chromatography over silica gel, to produce WG-391D as a white powder. Finally, WG-391D, 8-(3-hydroxypropylcarbamoyl)-N-phenylacetyl-1,3,4,9-tetrahydro-beta-carboline, was dissolved in DMSO at a concentration of 50 mM.

**Enzyme Assay**
The enzymic inhibition activity of WG-391D was measured using a "Human Protein Phosphatase Citc5 Combo Fluorometric Assay Kit" (Abnova, Taiwan, China), according to the manufacturer's instructions. In brief, 5 µL of WG-391D (100 µM in DMSO) was added into 40 µL of "Assay Mixture" (30 µL distilled water, 5 µL 10× assay buffer, and 5 µL 10× 3-O-methylfluorescein phosphate). The same volume of DMSO and NSC663284 (100 µM in DMSO, Sigma, USA) served as negative and positive controls, respectively. Enzyme reactions were initiated by adding 5 µL of recombinant CDC25B protein and then preincubated at room temperature for 5–8 min. Fluorescence intensity was then measured for 60 min at 5 min intervals, using excitation and emission wavelengths of 485 and 525 nm, respectively.

**Cell Proliferation Assay**
Cells (2 × 10^4/ml in a total volume of 100 µl per well) were seeded into 96-well plates and cultured overnight. WG-391D was added at a series of concentrations up to 33.33 µM, and cells cultured for a further 72 h. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulfophenyl)- 2H-tetrazolium (MTS) assay, using a Cell Proliferation Assay kit (G5430, Promega, Wisconsin, USA), in accordance with the manufacturer's instructions, and IC50 values calculated.

**Cell Migration Assay**
Transwells, containing polycarbonate membrane filter inserts with 8-µm pore size (Costar Group, DC, USA), were inserted into 24 well cell culture plates. Cells (5 × 10^4 in 200 µl RPMI 1640, without FBS, per well) were seeded into the upper chambers. RPMI 1640 containing 10 % FBS (700 µl per well) was added into the 24 well plates. Cells were cultured for 18 h. After fixing with 4 % paraformaldehyde, cells were stained with 2% crystal violet. Non-migrating cells on the upper chamber surface were scraped out and five random fields of migrated cells on the underside of the membrane were photographed under a microscope and migrated cells were counted.

**Cell Cycle Assay**
SKOV3 cells (1 × 10^3/ml in 2 ml per well) were seeded into 6-well plates and cultured overnight. WG-391D was added at the indicated concentrations. Cells were cultured for a further 6 to 48 h. After fixing in 70% ethanol at 4°C for 24 h, cells were stained with 50 µg/ml propidium iodide (PI), containing 400 U/ml RNase A, for 30 min at room temperature in the dark. Cells were measured using a FACSCalibur flow cytometer (BD Biosciences, CA, USA) within 2 h of staining. Cell cycle distribution was analyzed using ModFit LT software (Verity Software House, ME, USA).

**Cell Apoptosis Assay**
SKOV3 cells (1 × 10^3/ml in 2 ml per well) were seeded into 6-well plates and cultured overnight. WG-391D was added at increasing concentrations, from 0.2 to 25 µM. Cells were cultured for a further 6 to 24 h and stained using an Annexin V and PI staining kit (V13242, Thermo Fisher Scientific, MA, USA), according to manufacturer's instructions. Apoptotic cells were detected using a FACSCalibur (BD Biosciences) instrument, and analyzed using FlowJo software (FlowJo LLC, OR, USA).

**Xenografts in Nude Mice**
In order to generate PDX from patient GFY004, fresh ovarian tumor tissues (derived from surgery) were cut into 1–2 mm samples and punched into the left front flank of BALB/c nude mice and digested using a Tumor Dissociation Kit (130-095-929, Milteny, Teterow, Germany) in a water bath at 37°C for 45 min. Single cell suspensions were centrifuged at 150 x g for 5 min, then washed twice with RPMI 1640. Primary ovarian tumor cells were then cultured in RPMI 1640 containing 20% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. All primary tumor cell lines were cultured for 5 to 10 generations prior to experiments. Specific patient characteristics are detailed in **Table 1**.
mice by puncture needles. This represented the first generation of PDX. The diameters of the tumors that develop subsequently, would be 5–10 mm in size 1 month later. Mice were sacrificed 1 month after flank puncture and surgery was carried out to remove tumors. Tumors were cut into 1–2 mm samples and punched into the left front flank of nude mice, as described above; this represented the second generation of PDX models. The same procedure was used to generate a third generation of PDX models.

Five- to six-week-old BALB/c athymic nude mice were inoculated with 1 × 10⁶ SKOV3 cells, or 1–2 mm diameter third generation ovarian PDX from GFY004, under the left front flank. Seven days later, mice were treated with 25 mg/kg/day WG-391D continuously for a further 3 weeks. Tumor volume, and the body weights of the mice, were monitored at intervals of 1 or 2 days. Tumor volume was calculated using the following formula: volume = a × b × b/2, where “a” was the longer diameter and “b” the shorter one. After the mice were sacrificed, tumors were surgically removed and weighed.

**RNA Sequencing**

SKOV3 cells were treated with or without 5 μM WG-391D for 24 h. Assays were conducted using triplicate samples. Total RNA was extracted using TRIzol (Thermo Fisher SCIENTIFIC, MA, USA) and RNA sequencing libraries prepared using an Illumina Standard library preparation kit, according to the manufacturer’s instructions. mRNA expression levels were determined by RNA sequencing at Shanghai OE Biotech Co., Ltd (Shanghai, China) using the Illumina HiSeqTM 2500 platform, as previously described (31). Gene expression values were normalized as fragments per kilobase of transcript per million mapped reads (FPKM), and P < 0.05, generated using the DESeq Software Package (bioconductor.org/), were considered to be statistically significant.

**qRT-PCR**

SKOV3 cells were lysed in TRIzol for total RNA extraction after treatment with or without 5 μM WG-391D for 24 h. In order to measure CDC25B mRNA expression levels in various cell lines, SKOV3, OVCAR8, ES2, OVTOKO, A2780, HO8910PM, MCAS, HOSEPIC, IGROV1, GFY004, CZ001, CZ006, and CZ008 cells were lysed in TRizol without treatment. cDNA was generated using a Superscript III Reverse transcriptase kit (Life Technologies). The expression levels of target genes were then determined by SYBR® Green Real-time PCR master mix kit (Takara, Shiga, Japan) on a 7900HT machine (Applied Biosystems, Foster City, CA, USA). The primer pair, 5'-GCA TGGAGAGTCCTATTAGTGCC-3' and 5'-CTCCGCCTCGGC TTATTCT-3', was used to amplify CDC25B. The primers, 5'- ACCCAGAAACTGTGATGG-3' and 5'-TTCCAGGTCAGGG ATGACCTT-3', were used to amplify the housekeeping gene GAPDH as a control. Relative mRNA expression levels were expressed as the ratio of the levels of target genes to those of GAPDH using the ∆∆Ct method.

**Western Blotting**

Cells or tissues were lysed using RIPA buffer (Beyotime, Jiangsu, China) containing protease and phosphatase inhibitors. Protein concentrations were then measured using a BCA protein assay kit (Thermo Fisher Scientific). A total of 20 μg protein from SKOV3, HO8910PM, CZ001, CZ006, GFY004, and GFY005 cells, and 100 μg total proteins from ovarian tumor tissues, normal ovarian tissues, or xenograft tumors from nude mouse models, were subjected to SDS-PAGE on 10% gels and blotted onto nitrocellulose filter (NC) membrane by electrophoresis.

The following primary antibodies were used: anti-CDC25B (#D260980-0025; Sangon Biotech, Sangon, Shanghai, China); anti-AKT (#8272), anti-pAKT (ser473) (#8271), anti-PARP and –cleaved PARP (#9532), anti-CDC2 (#9116), and anti-pCDC2 (Tyr15) (#4539) (Cell Signaling Technology, Danvers, MA, USA); and anti-GAPDH (#AP0063) (Bioworld Technology, MN, USA). Goat anti-mouse (#926-32210, LI-COR Biosciences, NE, USA) or goat anti-rabbit (#926-32211, LI-COR) IRDye 800CW-labeled secondary antibodies were used for staining and detected using Image Studio Version 5.2 on an Odyssey CLx infrared imaging system (LI-COR).

**Online Database Analysis**

Correlations of CDC25B mRNA expression levels and PFS or post-progression survival (PPS) of ovarian cancer patients were analyzed using the Kaplan Meier-plotter online database (http://kmplot.com/analysis/index.php?p=service&cancer=ovar). Parameter cut-off values were selected using the auto select best cutoff function. This online tool has been described in a previous study by its creators (32).

Normalized CDC25B expression data from 902 ovarian tumors and 51 normal tissues were downloaded from the Gene Expression across Normal and Tumor tissue (GENT) online
database (http://medical-genome.kribb.re.kr/GENT/index.php). This public database has been described in a previous study by its creators (33).

**Statistical Analysis**

Two to three independent experiments, with at least three replicates, were conducted for all assays. Data are presented as mean ± standard deviation (SD). Figures were plotted using GraphPad Prism 5.0 software (GraphPad Software Inc., CA, USA). The statistical significance of differences between experimental groups was evaluated using GraphPad Prism 5.0 software. The two-tailed Student's t-test was performed for data which followed a Gaussian distribution, while the non-parametric Mann-Whitney test was used for non-Gaussian distributed data. Correlations between mRNA expression and the IC50s of WG-391D were analyzed using Pearson's method (for data with a Gaussian distribution) or Spearman's method (for data with a non-Gaussian distribution). Two way analysis of variance (ANOVA) was used to statistically analyze CDC25B catalytic dephosphorylation activity. A P < 0.05 was considered to be statistically significant.

**RESULTS**

**The Expression of CDC25B Is Highly Up-Regulated in Ovarian Cancer**

CDC25B expression levels were detected by western blotting in both ovarian tumors and normal ovarian tissue samples from the same patients. As shown in **Figure 1A**, CDC25B was over-expressed in ovarian tumors compared with normal ovarian tissues. The characteristics of ovarian cancer patients are presented in **Table 1**. To confirm the over-expression of CDC25B in ovarian tumors, normalized CDC25B expression data from 902 ovarian tumor and 51 normal tissue samples were downloaded from the GENT online database (33). As shown in **Figure 1B**, CDC25B was also significantly over-expressed in both primary ovarian tumor samples compared with normal tissues, p < 0.001. Also, high CDC25B expression levels were universally detected in both primary ovarian cancer cell lines (GYF004, GYF005, CZ001, and CZ006) and representative ovarian cancer cell lines (SKOV3 and HO8910PM) (**Figure 1C**). Analysis of mRNA array data (32), using the Kaplan Meier-plotter online database, showed that CDC25B overexpression was positively associated with poor PFS (**Figure 1D**) and PPS (**Figure 1E**) of ovarian cancer patients.

**WG-391D Inhibits the Expression of CDC25B in an Efficient Manner**

WG-391D is a novel small molecule compound, which was synthesized in our laboratory. The molecular formula and expected molecular weight of WG-391D are C23H25N3O3 and 391.47 Daltons, respectively. The molecular structure of WG-391D is shown in **Figure 2A**. RNA sequencing data showed that WG-391D significantly inhibited CDC25B mRNA expression without affecting that of CDC25A and CDC25C (**Figure 2B**). According to KEGG pathway analysis, which was carried out on our RNA sequencing data, CDC25B is the only gene that can be significantly inhibited by WG-391D among the genes involved in the promotion of G2/M phase transition (**Figure S1**). qRT-PCR assays confirmed that CDC25B was down-regulated by WG-391D (**Figure 2C**). Moreover, WG-391D reduced CDC25B protein levels in a dose-dependent manner (**Figures 2D,E**) and markedly reduced CDC25B protein levels at concentrations as low as 0.2 µM in SKOV3 cells (**Figure 2B**). As shown in **Figures 2D,E**, CDC25B down-regulation caused increased phosphorylation of CDC2, a downstream molecular target of CDC25B. CDC25B is known to be able to activate the serine/threonine kinase AKT in cancer cells treated with the mTOR inhibitor, rapamycin (34). Our data demonstrated that downregulation of CDC25B inhibited AKT phosphorylation. CDC2 phosphorylation and AKT dephosphorylation resulted in inactivation of CDC2 and AKT, respectively (**Figures 2D,E**). In the present study, we used an in vitro chemical assay to detect the effects of WG-391D on CDC25B catalytic dephosphorylation activity. As shown in **Figure 2F**, WG-391D had no effect upon CDC25B catalytic activity.

**WG-391D Efficiently Inhibits the Proliferation and Migration of Ovarian Cancer Cells**

The effect of WG-391D on ovarian cancer cell proliferation was detected by MTS assays. As shown in **Figure 3A**, the IC50 values of WG-391D for all five representative epithelial ovarian cancer cell lines (SKOV3, A2780, MCAS, ES2, and HO8910PM) were <1.00 µM. Of these ovarian cancer cell lines, A2780 is derived from a serous subtype, MCAS from a mucinous subtype, ES2 from a clear cell subtype, and HO8910PM from an endometrioid tumor. These represent the four major histological ovarian carcinoma subtypes. And the subtype of SKOV3 is unclear. In contrast, the IC50 value of WG-391D for a normal ovarian epithelial cell line, HOSEPIC, was >33.33 µM (**Figure 3A**), indicating that WG-391D may be selectivity tolerant.

A total of eight different ovarian cancer cell lines (SKOV3, ES2, OVCA8, OVTOKO, A2780, IGROV1, HO8910PM, and MCAS), including all four major histological subtypes of epithelial ovarian cancer, and four differing primary ovarian tumor cell lines (GYF004, CZ001, CZ006, and CZ008), were included in our experiments in order to confirm the high efficiency of WG-391D in terms of the inhibition of ovarian cancer cell proliferation. GYF004 and CZ006 are high grade serous carcinomas, CZ001 is a clear cell carcinoma, and CZ008 is a poorly differentiated carcinoma. As shown in **Figure 3B**, the IC50 values of WG-391D for inhibition in all of these cell lines were <10 µM. To analyze the correlations between CDC25B expression levels and the inhibitory rates of WG-391D, we correlated CDC25B mRNA expression levels and the IC50 of WG-391D. In all thirteen cell lines (SKOV3, ES2, OVCA8, OVTOKO, A2780, IGROV1, HO8910PM, MCAS, HOSEPIC, GYF004, CZ001, CZ006, and CZ008), CDC25B expression levels trends to show a negative correlation with the IC50 of WG-391D (**Figure 3C**, left panel). These cells were then divided into two groups, the first group (OVCA8, ES2, OVTOKO, A2780, HO8910PM, MCAS, GYF004, CZ001, and CZ006) featured low CDC25B expression levels and low WG-391D IC50. The second
CDC25B is over-expressed in ovarian tumors and ovarian cancer cell lines. (A) CDC25B expression was detected in ovarian tumor and normal ovarian tissue samples from the same patients by western blot assay. Total proteins (100 µg per sample) were analyzed. CA, carcinoma; CN, control. (B) Statistical analysis of CDC25B expression levels in tumor and normal tissue samples using data downloaded from the GENT database. N, sample number. ** * p < 0.001. (C) CDC25B expression levels were detected in primary ovarian tumor cell lines (CZ001, CZ006, GFY004, and GFY005) and ovarian cancer cell lines (SKOV3 and HO8910PM) by western blot assay. Total proteins (20 µg per sample) were analyzed. (D,E) Analysis of the relationship between CDC25B expression levels and ovarian cancer patient progression-free survival periods (PFS) and post-progression survival (PPS) periods using the Kaplan Meier-plotter website.

Cancer cell migration ability in vitro is positively correlated with cell invasion and metastasis in vivo. Here, we also evaluated the effect of WG-391D on the migration of ovarian cancer cells. The SKOV3 cell line exhibits strong migratory ability, and is one of the most studied cell models of epithelial ovarian carcinoma. As shown in Figure 3D, WG-391D significantly decreased SKOV3 cell migration at concentrations as low as 0.008 µM. The IC50 value of WG-391D for inhibition of SKOV3 cell migration was <0.2 µM (Figure 3D). To verify the efficiency of WG-391D in inhibiting ovarian cancer cell migration, three ovarian cancer cell lines (SKOV3, ES2, and OVCAR8), and three primary ovarian tumor cell lines (GFY004, GFY005, and CZ006), were included in the migratory assay. Cells were allowed to migrate for ~18 h in the presence of 1 µM WG-391D. As shown in Figure 3E, the IC50 values of WG-391D for the inhibition of cell migration were <1 µM in all six of these cell lines.
WG-391D Induces Cell Cycle Arrest at the G2/M Phase and Induces Apoptosis in Ovarian Cancer Cells

The effects of WG-391D on ovarian cancer cell cycle progression and apoptosis were detected by FACS flow cytometry. Our data show that WG-391D inhibited SKOV3 cell cycle progression at the G2/M phase in a dose-dependent manner. WG-391D could strongly inhibit SKOV3 cell cycle progression at concentrations as low as 0.2 μM, when administered for 24 h (Figure 4A). Furthermore, WG-391D inhibited SKOV3 cell cycle progression in a time-dependent manner. WG-391D could induce cell cycle arrest in as short a time as 6 h at a concentration of 5 μM (Figure 4B). Moreover, WG-391D induced SKOV3 cell apoptosis in a dose- and time-dependent manner. WG-391D induced SKOV3 cell apoptosis at concentrations as low as 0.2 μM, when treated for 24 h (Figure 4C). Treatment with 5 μM WG-391D strongly induced cell apoptosis in as short a time as 6 h (Figure 4D). Cell apoptosis induced by WG-391D was also demonstrated by the induction of cleaved PARP in SKOV3 cells treated with WG-391D (Figure 4E). These data demonstrate that WG-391D causes SKOV3 cell cycle arrest and induces apoptosis in a dose- and time-dependent manner.

WG-391D Inhibits Ovarian Tumorigenesis in Nude Mice

PDX models can better simulate the heterogeneity and genetic complexity of tumors in vivo. In creating our model, we were able to demonstrate similar morphology (e.g., glands, papillae, stromal cores, and desmoplastic stroma) of our PDX model across three generations (Figure S3). GFY004 is a high grade serous ovarian carcinoma and, as a PDX, grew very rapidly in nude mice and contained various types of cell with differing morphologies. Therefore, this PDX represented a good simulation of the heterogeneity and genetic complexity of high grade serous ovarian carcinoma. Five- to six-week-old female BALB/c athymic nude mice were inoculated under the left front flank with third generation PDX from GFY004, or with SKOV3 cells. Seven days later, mice were intraperitoneally administered with 25 mg/kg/day WG-391D for a further 3 weeks. Our results showed that tumor volume and tumor weight were inhibited by WG-391D in both SKOV3 cell xenografts (Figures 5A,B) and the PDX mouse models (Figures 5E,F). The inhibitory effect of WG-391D on ovarian cancer in vivo was also reflected by the inhibition of Ki67 expression in tumors from nude mice treated with WG-391D (Figure S2). WG-391D could protect tumor-bearing nude mice from body weight loss in the SKOV3 cell
Figure 3 | WG-391D strongly inhibits ovarian cancer cell proliferation and migration. (A) Cell lines were treated with increasing concentrations of WG-391D and cell viability determined by MTS assay. Error bars, mean ± SD. (B) IC50 values of WG-391D on eight ovarian cancer (SKOV3, OVCAR8, ES2, OVTOKO, A2780, HO8910PM, and MCAS) and four primary ovarian tumor (GFY004, CZ001, CZ006 and CZ008) cell lines were measured by MTS assay. (C) Correlations of CDC25B mRNA expression levels (detected by qRT-PCR) with the IC50s of WG-391D were analyzed. Left panel: Correlations of CDC25B expression levels and the IC50s of WG-391D detected in all ovarian cell lines (SKOV3, OVCAR8, ES2, OVTOKO, A2780, HO8910PM, MCAS, HOSEPIC, IGROV1, GFY004, CZ001, CZ006, and CZ008) involved in panels (A,B). Middle panel: Analysis of the correlations between CDC25B expression levels and the IC50s of WG-391D to nine cell lines (OVCAR8, ES2, OVTOKO, A2780, HO8910PM, MCAS, GFY004, CZ001, and CZ006) with low CDC25B expression levels and low WG-391D IC50s. Right panel: Analysis of the correlations between CDC25B expression levels and the IC50s of WG-391D in four cell lines (SKOV3, IGROV1, HOSEPIC and CZ008) with high CDC25B expression or high IC50s for WG-391D. (D) The effects of WG-391D on SKOV3 cell migration were measured. Upper panel, representative data showing migrated SKOV3 cells following treatment with different concentrations of WG-391D for 18 h. Lower panel, statistical analysis of SKOV3 cell migration data. (E) Migration inhibitory ratios were calculated for various ovarian cancer (SKOV3, ES2, and OVCAR8) and primary ovarian tumor (GFY004, GFY005, and CZ008) cell lines treated with 1 µM WG-391D for 18 h. Untreated cells were used as negative controls. ***p < 0.001.

In summary, WG-391D inhibited the expression of CDC25B, and inactivated both CDC2 and AKT in xenografts from nude mice inoculated with SKOV3 cells (Figure 5D), or a third generation PDX from patient GFY004 (Figure 5H).

DISCUSSION

Ovarian cancer is the fifth leading cause of cancer death among gynecological malignances, and has the highest mortality rate...
FIGURE 4 | WG-391D induces ovarian cancer cell cycle arrest at G2/M phase and apoptosis. (A, C) SKOV3 cells were treated with the indicated concentrations of WG-391D for 24 h. (B, D) SKOV3 cells were treated with 5 µM WG-391D for different periods of time. (A, B) Cells were stained by PI and cell cycle phase distribution analyzed using ModFit software. (C, D) Cells were stained using Annexin V and PI. Apoptotic cells were analyzed using Flowjo software. Upper panel, representative images; lower panel, statistical analysis of data. (E) Cells were treated with WG-391D, or paclitaxel, at the indicated concentrations for 24 h. PARP and cleaved PARP (PARP CL) were then detected by western blot assay. Total proteins (100 µg per sample) were analyzed. GAPDH served as a house-keeping control. ***p < 0.001.

[~60% of all female tumors (1)]. More than two thirds of ovarian cancer patients have advanced disease at diagnosis, and almost all of them develop a recurrence after radical surgery and chemotherapy. Although a great deal of effort has been applied to the development of novel drugs and strategies for the treatment of ovarian cancer, the median 5-year OS rate has remained at a low level (30–40%) for the past two decades1. As ovarian cancer is a highly heterogeneous malignancy, a better understanding of its underlying mechanisms would greatly facilitate the search for superior rational and efficient target therapies.

Signaling molecules with key roles in ovarian cancer deterioration are of great significance as potential targets for the development of therapies for ovarian cancer. This study shows that CDC25B is strongly over-expressed in ovarian tumors compared with normal ovarian tissues and that CDC25B is universally strongly expressed in ovarian cancer and primary ovarian tumor cell lines. Consistent with our study, Broggini et al.
FIGURE 5 | WG-391D strongly inhibits ovarian cancer tumorigenesis in vivo. BALB/c athymic nude mice were inoculated with $1 \times 10^6$ SKOV3 cells (A–D), or third generation PDX from patient GFY004 (E–H), under the left front flank. Seven days after inoculation, mice were treated with 25 mg/kg/day WG-391D, or the same volume of DMSO as a negative control, for a further 3 weeks. Tumor volume (A, E) and mice body weights (C and G) were monitored on the indicated days. (B, F) Tumors were weighed after mouse were sacrificed. Upper panel, tumor images. Lower panel, statistical analysis of data. (D, H) Expression (CDC25B, CDC2, AKT, and GAPDH) and phosphorylation (pCDC2 and pAKT) of CDC25B, CDC2, and/or AKT in xenografts were detected by western blot (upper panel). Total proteins (100 µg per sample) were analyzed. GAPDH served as a house-keeping control. In the lower panel, band densities were measured by Image Pro Plus software. Differences of band densities between WG-391D treated groups and control groups were statistically analyzed. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. 
also reported that CDC25B is universally expressed in ovarian cancer and associated with poor prognosis (35). Furthermore, CDC25B over-expression can activate AKT, and the co-inhibition of AKT and CDC25 has synergistic effects in the suppression of the growth of triple-negative breast cancer cells (34, 36). These studies highlight CDC25B as an attractive and rational target for cancer treatment (37).

Vitamin K analogs (23), NSC 663284 (24), naphthofuran-4,5-dione 3-benzoyl-naphtho[1,2-b][furan-4,5-dione (5169131) (25), adociquinone B (26), IRC-083864, and BN82685 (27, 28) are the most potent CDC25B inhibitors reported to date; however, none of these compounds have entered clinical trials for ovarian cancer therapy. These inhibitors were all identified using in vitro chemical assays because of their high activity in inhibiting the catalytic dephosphorylation activity of CDC25B. Interestingly, a previous study reported that the compound CHEQ-2 not only inhibited CDC25A and CDC25B catalytic activity in vitro, but also caused down-regulation of CDC25A and CDC25B at doses higher than ~15 µM in human colon cancer (HT-29), breast cancer (MCF-7), and hepatocellular carcinoma (HepG2) cells (29). Importantly, this type of inhibitor could avoid the reversion of catalytic activity inhibition by high levels of CDC25 expression. When evaluating the ability of compounds from our laboratory's compound pool to down-regulate CDC25B by western blotting, we found that WG-391D could down-regulate CDC25B at doses as low as 0.2 µM, indicating that WG-391D was a powerful CDC25B inhibitor. Moreover, WG-391D was a CDC25B-specific inhibitor that did not affect the expression of CDC25A or CDC25C. All previously reported CDC25B inhibitors were not specific for CDC25B, and also exhibited inhibitory activity against CDC25A and/or CDC25C (37). Therefore, WG-391D could be valuable for the development of chemotherapeutics for cancer treatment. WG-391D is a highly efficient inhibitor of ovarian cancer cell proliferation and migration, with IC_{50} values <10 and 1 µM, respectively. The underlying mechanisms were associated with the down-regulation of CDC25B and the subsequent inactivation of CDC2 and AKT. Furthermore, we found that the inhibitory rates of WG-391D against proliferation correlated positively with CDC25B expression levels. WG-391D induces cell cycle arrest at the G2/M phase, and apoptosis. As more than 90% of ovarian cancers are high grade serous ovarian carcinomas, this study used a high grade serous ovarian carcinoma PDX model to evaluate the antitumor activity of WG-391D. In nude mice xenograft model experiments, we showed that WG-391D could significantly inhibit tumor growth in both SKOV3 cells and PDX mouse models. Furthermore, WG-391D could prevent the loss of body weight in mice. These data prove that WG-391D is an efficient inhibitor of ovarian cancer, with tolerable cytotoxicity.

WG-391D and YR290 share the same scaffold. Consequently, the direct target of WG-391D should also be TGFBR1. Sp1 is an essential transcriptional promotion factor of CDC25B (39, 40), and E2F4 is a proven transcriptional repressor of CDC25B (41). The E2F4-p107 complex can directly inhibit Sp1 transcriptional activity by binding with Sp1 with p107 (42). According to our RNA sequencing data, Sp1 is highly down-regulated and E2F4 up-regulated by WG-391D. Also, a previous study showed that CDC25B could phosphorylate and activate AKT (34). Combining these previous publications and our present research data, we propose that WG-391D operates mainly through a signaling pathway involving TGFBR1-MYC-CDKN2C-CycD-p107-E2F4/Sp1-CDC25B-CDC2/AKT. The expression levels of genes associated with this pathway are shown in Table S1. This mechanistic model is also given as a flowchart in Figure 6. This study indicates that CDC25B down-regulators may be valuable for the clinical treatment of ovarian cancers.

CONCLUSIONS

In conclusion, this study demonstrated that CDC25B was over-expressed in ovarian cancers. WG-391D efficiently inhibited ovarian cancer cell proliferation and migration, was associated with the induction of cell cycle arrest at G2/M phase and apoptosis, and inhibited the tumorigenesis of ovarian cancer in both SKOV3 cell and PDX BALB/c athymic nude mouse models. The anti-tumor activity of WG-391D involved down-regulation of CDC25B, which demonstrated that YR-290 is an inhibitor of TGFBR1 and induces cell cycle arrest at the G2/M phase with the induction of cell cycle arrest at G2/M and apoptosis. Therefore, WG-391D and YR290 share the same scaffold. Consequently, the direct target of WG-391D should also be TGFBR1. Sp1 is an essential transcriptional promotion factor of CDC25B (39, 40), and E2F4 is a proven transcriptional repressor of CDC25B (41). The E2F4-p107 complex can directly inhibit Sp1 transcriptional activity by binding with Sp1 with p107 (42). According to our RNA sequencing data, Sp1 is highly down-regulated and E2F4 up-regulated by WG-391D. Also, a previous study showed that CDC25B could phosphorylate and activate AKT (34). Combining these previous publications and our present research data, we propose that WG-391D operates mainly through a signaling pathway involving TGFBR1-MYC-CDKN2C-CycD-p107-E2F4/Sp1-CDC25B-CDC2/AKT. The expression levels of genes associated with this pathway are shown in Table S1. This mechanistic model is also given as a flowchart in Figure 6. This study indicates that CDC25B down-regulators may be valuable for the clinical treatment of ovarian cancers.
of CDC25B and subsequent inactivation of CDC2 and AKT. In conclusion, our data demonstrate that WG-391D has potential to be very valuable for the development of chemotherapeutic drugs for use in ovarian cancer therapy.

ETHICS STATEMENT

Written informed consent was obtained from all individual participants. This study was conducted according to the Declaration of Helsinki and approved by the Ethical Committee of Fengxian District Central Hospital. All animal experiments were performed according to the Guidelines of the Laboratory Animal Ethical Board, and approved by the Animal Care and Use Committee of East China Normal University School of Life Sciences.

AUTHOR CONTRIBUTIONS

YX designed and performed the experiments and drafted the manuscript. YY, DG, WJ, YS, and PZ participated in the experiments. PJ, YL, CW, FG, CZ, and BW were involved in resource collection. RZ, BD, and YC supervised this study. All authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 81702563 to YX, 81472445 and 81672587 to RZ, 81673304 to YC, and 81603028 to YS), the Scientific and Technological Innovation Act Program of Shanghai Science and Technology Commission (4411973100 to RZ and 15431902200 to YC), and the Natural Science Foundation of Shandong Province (ZR2016HB26 to YS).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.00236/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68:7–30. doi: 10.3322/caac.21442
2. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. (2011) 11:719–25. doi: 10.1038/nrcr3144
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. (2015) 65:87–108. doi: 10.3322/ caac.21262
4. Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. (2017) 41:339–52. doi: 10.1016/j.bpobyn.2016.12.001
5. Cortesi L, Toss A, Cucinotto I. Parp inhibitors for the treatment of ovarian cancer. Curr Cancer Drug Targets. (2018) 18:877–93. doi: 10.2174/1568009618666180308104646
6. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. (2014) 15:852–61. doi: 10.1016/S1470-2045(14)70288-1
7. Pujade-Lauraine E, Ledermann JA, Selle F, Gabski V, Pensin RT, Ozà AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov2 1): Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. J Clin Oncol. (2016) 34:2271–8. doi: 10.1200/JCO.2015.63.2596
8. Schmid BC, Oehler MK. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Curr Treat Options Oncol. (2015) 16:318. doi: 10.1007/s11864-014-0318-0
9. Khalid DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. (2016) 13:273–90. doi: 10.1038/nrclinonc.2016.25
10. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. (2012) 366:2455–65. doi: 10.1056/NEJMoa1200694
11. Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. (2016) 3:11. doi: 10.1186/s40661-016-0033-6
12. De Souza CP, Ellem KA, Gabrielli BG. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res. (2000) 257:11–21. doi: 10.1006/excr.2000.8872
13. Lindqvist A, Kallstrom H, Lundgren A, Borsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol. (2005) 171:35–45. doi: 10.1083/jcb.200503066
14. Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B. Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther. (2006) 5:1446–51. doi: 10.1158/1535-7163.MCT-06-0099
15. Boutsos R, Lobajova V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. (2007) 7:493–507. doi: 10.1038/nrc2169
16. Albert H, Santos S, Battaglia E, Brito M, Monteiro C, Bagrel D. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells. Clin Chem Lab Med. (2011) 49:1707–14. doi: 10.1515/cclm.2011.635
17. Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Malloffe C, et al. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. (2001) 81:465–73. doi: 10.1038/labinvest.3780254
18. Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, Lu KH. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res. (2003) 63:6915–9.
19. Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. J Transl Med. (2004) 2:71–81. doi: 10.1186/1479-5876-2-71
20. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene. (2004) 23:71–81. doi: 10.1038/sj.onc.1206926
21. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Fontanini G. CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Hum Pathol. (2007) 38:1563–8. doi: 10.1016/j.humpath.2007.03.006
22. Kar S, Wang M, Ham SW, Carr BL. Fluorinated Cpd 5, a pure arylation K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting
Cdc25 and activating MAPK. Biochem Pharmacol. (2006) 72:1217–27. doi: 10.1016/j.bcp.2006.07.024

24. Lazo JS, Aslan DC, Southwick EC, Cooley KA. Ducruet AP, Joo B, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. (2001) 44:4042–9. doi: 10.1021/jm0102046

25. Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol. (2004) 66:824–33. doi: 10.1124/mol.104.001784

26. Cao S, Foster C, Brisson M, Lazo JS, Kingston DG. Halenaquinone and xestosponquino derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem. (2011) 15:999–1003. doi: 10.1016/j.bmc.2004.11.039

27. Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther. (2005) 4:1378–87. doi: 10.1158/1535-7163.MCT-05-0168

28. Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer. (2009) 124:1449–56. doi: 10.1002/ijc.24080

29. Song Y, Lin X, Kang D, Li X, Zhan P, Liu X, et al. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent Cdc25 inhibitor and promising anticancer drug candidate. Eur J Med Chem. (2014) 82:293–307. doi: 10.1016/j.ejmech.2014.05.063

30. Zheng C, Fang Y, Tong W, Li G, Wu H, Zhou W, et al. Synthesis and biological evaluation of novel tetrahydro-beta-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-beta signaling pathway. J Med Chem. (2014) 57:600–12. doi: 10.1021/jmc401117i

31. Zhang Z, Zheng X, Yang J, Messing J, Wu Y. Maize endosperm-specific transcription factors O2 and PBF network the regulation of protein and starch synthesis. Proc Natl Acad Sci USA. (2016) 113:10842–7. doi: 10.1073/pnas.1613721113

32. Gyoryfy B, Lanczyk A, Szallas Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. (2012) 19:197–208. doi: 10.1530/ERC-11-0329

33. Shin G, Kang TW, Yang S, Back SJ, Jeong YS, Kim SY. GENT; gene expression database of normal and tumor tissues. Cancer Inform. (2011) 10:149–57. doi: 10.4137/CIN.S7226

34. Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, Chen YL, et al. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res. (2009) 69:2663–8. doi: 10.1158/0008-5472.CAN-08-3222

35. Broggin M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. (2000) 20:4835–40.

36. Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. (2018) 23:112–26. doi: 10.1016/j.celrep.2018.03.039

37. Brezak MC, Kasprzyk PG, Galcera MO, Lavergne O, Prevost GP. CDC25 inhibitors as anticancer agents are moving forward. Anticancer Agents Med Chem. (2008) 8:857–62. doi: 10.2174/187152008786847701

38. Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, et al. Inhibition of breast cancer metastases by a novel inhibitor of TGFbeta receptor 1. J Natl Cancer Inst. (2013) 105:47–58. doi: 10.1093/jnci/djs485

39. Korner K, Jerome V, Schmidt T, Muller R. Cell cycle regulation of the murine cdc25B promoter: essential role for nuclear factor-Y and a proximal repressor element. J Biol Chem. (2001) 276:9662–9. doi: 10.1074/jbc.M008696200

40. Dalvai M, Mondesert O, Bourdon JC, Ducommun B, Dozier C. Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene. (2011) 30:2282–8. doi: 10.1038/onc.2010.588

41. Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, et al. p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene. (2014) 33:3939–69. doi: 10.1038/onc.2013.378

42. Parakati R, DiMario JX. Dynamic transcriptional regulatory complexes, including E2F4, p107, p130, and Sp1, control fibroblast growth factor receptor signaling in myogenesis. J Biol Chem. (2005) 280:21284–94. doi: 10.1074/jbc.M410744200

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer SZ declared a shared affiliation, though no other collaboration, with several of the authors YS, PZ to the handling editor.